Short Interest in Stealth BioTherapeutics Corp (NASDAQ:MITO) Increases By 60.5%

Stealth BioTherapeutics Corp (NASDAQ:MITOGet Rating) saw a large increase in short interest during the month of April. As of April 30th, there was short interest totalling 728,200 shares, an increase of 60.5% from the April 15th total of 453,700 shares. Based on an average daily trading volume, of 629,700 shares, the days-to-cover ratio is currently 1.2 days.

Stealth BioTherapeutics stock traded down $0.02 during trading hours on Friday, reaching $0.23. 5,388,614 shares of the stock were exchanged, compared to its average volume of 1,470,208. The stock has a market cap of $13.54 million, a P/E ratio of -0.55 and a beta of 2.07. Stealth BioTherapeutics has a 52-week low of $0.17 and a 52-week high of $2.10. The firm’s 50 day moving average is $0.51 and its 200 day moving average is $0.71.

A hedge fund recently bought a new stake in Stealth BioTherapeutics stock. Geode Capital Management LLC purchased a new stake in Stealth BioTherapeutics Corp (NASDAQ:MITOGet Rating) in the third quarter, according to the company in its most recent filing with the SEC. The firm purchased 24,502 shares of the company’s stock, valued at approximately $33,000. Hedge funds and other institutional investors own 1.52% of the company’s stock.

Separately, HC Wainwright restated a “buy” rating and set a $4.00 price objective on shares of Stealth BioTherapeutics in a research report on Thursday, March 17th.

About Stealth BioTherapeutics (Get Rating)

Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate is Elamipretide that is in phase 3 clinical trial to treat barth syndrome, phase 2/3 clinical trial for the treatment of duchenne cardiomyopathy, phase 2a clinical trial to treat friedreich's ataxia, phase 2 clinical trial for the treatment of dry age-related macular degeneration, phase 2 clinical trial to treat leber's hereditary optic neuropathy, and phase 3 clinical trial for the treatment of replisome myopathies.

Further Reading

Receive News & Ratings for Stealth BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stealth BioTherapeutics and related companies with's FREE daily email newsletter.